Major PBM Reforms Advance in Congress as DOL Proposes New PBM Fee-Disclosure Rule
PUBLISHED
February 4th, 2026
DeAnn Deck
Federal oversight efforts directed at the pharmaceutical benefit manager (PBM) industry have accelerated in recent weeks. On Jan. 22, 2026, the House of Representatives passed the Consolidated Appropriations Act (CAA) of 2026, a funding package containing a broad range of (…)
There’s more to Read